Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Forte Biosciences, Inc.NASDAQ: FBRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$21.74M, compared with -$15.64M a year earlier. Trailing-twelve-month EBITDA was -$74.38M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -92.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.74M+8.4% QoQ
- Last fiscal yearDec 2025
- -$68.27M-92.7% YoY
- LTMMar 2026
- -$74.38M-70.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -39.0% | +100.0% | +139.0 pp |
| 1 year | -92.7% | +100.0% | +192.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (68.27M) USD
- Year-over-year change
- -92.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.27M) | -92.7% |
| FY2024 | 2024-12-31 | (35.44M) | -12.6% |
| FY2023 | 2023-12-31 | (31.47M) | -127.3% |
| FY2022 | 2022-12-31 | (13.84M) | +36.1% |
| FY2021 | 2021-12-31 | (21.67M) | — |
EBITDA vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -70.3% is the lowest of 10, against a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.52M USD | +14.5% | — | — |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.68M USD | +23.9% | — | — |
| LTM Mar 2026 | -$43.73M USD | +9.5% | — | 8329.5% | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$74.38M USD | -70.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$84.28M USD | -67.4% | — | — | |
| LTM Mar 2026 | -$90.7M USD | +10.7% | — | — | |
| LTM Mar 2026 | -$116.42M USD | -1.3% | — | 632.1% | |
| LTM Mar 2026 | -$117.42M USD | +23.4% | — | 1859.1% | |
| Peer median (excluding FBRX) | — | +10.7% | — | 1859.1% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.